According to the most recent report filed with the Securities and Exchange Commission by Assenagon Asset Management S.A., the company’s holdings in Cara Therapeutics, Inc. (NASDAQ: CARA) were reduced by 31.0% during the third quarter of 2018. The corporation finished the period with a holding of 32,700 shares of the stock of the biopharmaceutical business, having sold 14,698 shares during the quarter. Assenagon Asset Management S.A. disclosed to the Securities and Exchange Commission in its most recent report that it owned $306,000 worth of Cara Therapeutics, equivalent to 0.06% of the company. This information was included in the report that the company submitted.
Alterations have been made to the stock holdings of other investors, including individual investors, institutional investors, and hedge funds, among others. KBC Group NV made a brand new investment in the amount of $36,000 in Cara Therapeutics during the second quarter of the fiscal year. Through the second quarter, Mutual of America Capital Management LLC was able to amass an additional 17.9 percent of the total number of shares of Cara Therapeutics’ common stock. Mutual of America Capital Management LLC increased the number of shares it owned in the biopharmaceutical company during the most recent quarter by purchasing an additional 1,078 shares. This brought the total number of shares it owned in the company to 7,111, with a value of $65,000. In the first three months of this year, Federated Hermes Inc. increased the proportion of Cara Therapeutics stock owned by 27.7%. After making a new purchase of 1,302 shares during the most recent quarter, Federated Hermes Inc. now owns a total of 6,009 shares of the biopharmaceutical company, which have a value of $73,000. The shares were acquired as part of the most recent quarter. Cetera Advisor Networks LLC made a new investment in Cara Therapeutics, totaling approximately $93,000 during the second quarter of 2018. Last but not least, during the second quarter, Rafferty Asset Management LLC purchased a new stake in Cara Therapeutics for a sum that came to approximately $97,000 in total. At present, institutional investors such as hedge funds and other types of institutional investors own 69.26% of the shares in the company.
Recently, a significant number of equity analysts have published studies that they have written on the CARA stock. An article on StockNews.com that was first published on October 12 provided readers with their first exposure to Cara Therapeutics. They recommended that shareholders “hold” their shares of the company. Piper Sandler stated that they would be lowering their price objective on Cara Therapeutics to $25.00 in a research report published on Tuesday, November 15, and November 15. The report was about the company’s stock. Two groups of financial analysts have suggested that investors purchase the company; however, one of those analysts has also suggested that investors simply keep their existing positions. According to the data provided by Bloomberg, the company is currently rated as having an average rating of “Moderate Buy,” and the general price objective for the company is set at $26.60. In addition, the price target for the company is set at $26.60.
On Wednesday, trading on the NASDAQ CARA began with an opening price of $10.72. The price of the stock, as measured by its moving average over the past 200 days, is currently $10.34, while the price of the stock, as measured by its moving average over the past 50 days, is currently $11.07. The company’s current market capitalization is $576.03 million, and it has a price-to-earnings ratio that comes in at -6.46, giving it a beta value of 1.00. Over the past year, the price of a share of Cara Therapeutics, Inc. has varied from $7.40 to $13.97. In the previous twelve months, the price reached a new all-time high of $13.97.
On Monday, November 7 November 7, after the market had closed for the day, Cara Therapeutics (NASDAQ: CARA) announced its most recent quarterly results report. The biopharmaceutical company reported earnings per share for the quarter of $0.43, which was $0.01 less than the consensus estimate of $0.42 held by industry analysts. Cara Therapeutics had a return on equity that was negative by 43.13 percent, and the company had a negative net margin of 224.51 percent. The revenue for the company’s most recent fiscal quarter came in at $10.81 million, significantly higher than the estimated $8.39 million that industry experts provided. The projections of the market researchers indicated that Cara Therapeutics, Inc. would incur a loss of 1.31 cents on each share during the current fiscal year.
A further item worthy of note is that on Wednesday, December 21, 2018, an insider working for the company named Joana Goncalves sold a total of 2,992 shares of the stock belonging to the company. The number of shares traded came to a total of $33,719.84, and each share sold for an average price of $11.27. This resulted in the accumulation of cash. Following the completion of the transaction, the corporate insider now possesses 71,901 shares of the company, the combined value of which is $810,324.27. You can acquire additional information regarding the transaction if you click on the link provided for you. This link will take you to an official document presented to the Securities and Exchange Commission. On Wednesday, December 21 December 21, Senior Vice President Frederique Menzaghi, Ph.D., sold 3,506 shares of the company’s stock. This was one of the other things that took place during the events. It was determined that a total of $39,512.62 worth of the stock was traded at an average price of $11.27 per share, which resulted in cash accumulation. Following the successful conclusion of the transaction, the senior vice president was awarded ownership of 166,275 shares in the company. The total value of these shares is $1,873,919.25. If you follow the link, which will take you to a legal file submitted to the SEC, you will have the opportunity to acquire additional information regarding the transaction. On top of that, company insider Joana Goncalves sold 2,992 shares of the company’s stock on December 21 and December 21. The number of shares traded came to a total of $33,719.84, and each share sold for an average price of $11.27. This resulted in the accumulation of cash. Once the transaction is finalized, the company insider will have a direct ownership stake in 71,901 shares, each of which has a value of $810,324.27. Disclosures that are related to the sale might be found in this section of the website. Over the past three months, company insiders have offloaded 20,968 shares of company stock, bringing in a total of $234,284 in proceeds from the sales. 3.20 company insiders own a percent of the total shares currently outstanding.
The biopharmaceutical company, known as Cara Therapeutics, Inc., in the United States, is currently in the preliminary stages of commercialization. Its primary mission is to develop and commercialize chemical entities that selectively target kappa opioid receptors to relieve pruritus and pain. This is the company’s primary focus. This is one of the most important aims of the company. The company is currently working on the development of potential product candidates that will focus on the body’s immune system as well as the peripheral nervous system.